Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Evaluating the feasibility, preliminary efficacy, and safety of psilocybin- assisted psychotherapy for treatment- resistant obsessive- compulsive disorder: an open- label clinical trial.
FY 2022-23
Summary
The following proposed research is an open label clinical trial assessing the safety and clinical effects of the administration of psilocybin, a psychedelic commonly known as ‘magic mushrooms’, along with psilocybin assisted psychotherapy (PAP) in those with treatment resistant obsessive-compulsive disorder (OCD). Those with OCD often experience obsessions, which are thoughts or urges that are often undesirable and emotionally uncomfortable in nature. These obsessions are then followed by compulsions which are actions, mental or physical, that are usually performed in a repetitive manner in hopes to alleviate the obsessive thoughts. In this research, the aim is to assess whether psilocybin, can act as a therapeutic agent in alleviating symptoms of OCD in those that have not responded to other therapeutic options such as medications and therapy. Current research shows psilocybin is a strong candidate to treat other psychiatric disorders, such as depression and end of life anxiety. With the potential of psilocybin to alter brain network connectivity patterns that are implicated in OCD, psilocybin is a promising therapeutic for treatment-resistant OCD. Two psilocybin dosing sessions will take place in this trial, with each session including PAP sessions in which a trained clinician will guide the participant. Various scales will be used to assess and compare changes in OCD severity, and quality of life from before the sessions to after. The working hypothesis is that after two psilocybin dosing sessions, participants will experience decreased OCD severity. Importantly, this trial will inform larger scale studies to further understand the efficacy of psilocybin and PAP in treating OCD, improving quality of life for individuals with OCD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486642
Name
Baer Jenna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the feasibility, preliminary efficacy, and safety of psilocybin- assisted psychotherapy for treatment- resistant obsessive- compulsive disorder: an open- label clinical trial.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Trial; Neuroimaging; Obsessive Compulsive Disorder (Ocd); Psilocybin; Psilocybin Assisted Psychotherapy (Pap); Psychedelic; Psychiatric Disorders; Treatment Resistant Ocd
Abstract
The following proposed research is an open label clinical trial assessing the safety and clinical effects of the administration of psilocybin, a psychedelic commonly known as ‘magic mushrooms’, along with psilocybin assisted psychotherapy (PAP) in those with treatment resistant obsessive-compulsive disorder (OCD). Those with OCD often experience obsessions, which are thoughts or urges that are often undesirable and emotionally uncomfortable in nature. These obsessions are then followed by compulsions which are actions, mental or physical, that are usually performed in a repetitive manner in hopes to alleviate the obsessive thoughts. In this research, the aim is to assess whether psilocybin, can act as a therapeutic agent in alleviating symptoms of OCD in those that have not responded to other therapeutic options such as medications and therapy. Current research shows psilocybin is a strong candidate to treat other psychiatric disorders, such as depression and end of life anxiety. With the potential of psilocybin to alter brain network connectivity patterns that are implicated in OCD, psilocybin is a promising therapeutic for treatment-resistant OCD. Two psilocybin dosing sessions will take place in this trial, with each session including PAP sessions in which a trained clinician will guide the participant. Various scales will be used to assess and compare changes in OCD severity, and quality of life from before the sessions to after. The working hypothesis is that after two psilocybin dosing sessions, participants will experience decreased OCD severity. Importantly, this trial will inform larger scale studies to further understand the efficacy of psilocybin and PAP in treating OCD, improving quality of life for individuals with OCD.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Baer, Jenna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~